The in vitro addition of idarucizumab to plasma samples from patients increases thrombin generation

Abstract Dabigatran interferes with many coagulation tests. To overcome this obstacle the use of idarucizumab as an in vitro antidote to dabigatran has been proposed. The aim of this study was to test the effect of idarucizumab as an in vitro antidote to dabigatran in ex vivo plasma samples from rou...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mojca Božič Mijovski, Rickard E. Malmström, Nina Vene, Jovan P. Antovic, Alenka Mavri
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/a25cf96b94804dc3a82f82c18ba9f6e4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a25cf96b94804dc3a82f82c18ba9f6e4
record_format	dspace
spelling	oai:doaj.org-article:a25cf96b94804dc3a82f82c18ba9f6e42021-12-02T13:17:42ZThe in vitro addition of idarucizumab to plasma samples from patients increases thrombin generation10.1038/s41598-021-85318-y2045-2322https://doaj.org/article/a25cf96b94804dc3a82f82c18ba9f6e42021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-85318-yhttps://doaj.org/toc/2045-2322Abstract Dabigatran interferes with many coagulation tests. To overcome this obstacle the use of idarucizumab as an in vitro antidote to dabigatran has been proposed. The aim of this study was to test the effect of idarucizumab as an in vitro antidote to dabigatran in ex vivo plasma samples from routine clinical patients examined by a thrombin generation assay (TGA). From 44 patients with atrial fibrillation five blood samples were collected. Thrombin generation was measured in all samples before and after the addition of idarucizumab. When idarucizumab was added to baseline plasma (no dabigatran), it caused a significantly shorter Lag Time and Time to Peak Thrombin, and a higher Peak Thrombin and Endogenous Thrombin Potential (ETP) of TGA. Similar results were obtained when idarucizumab was added to dabigatran-containing plasma, with TGA parameters comparable to baseline + idarucizumab plasma, but not to baseline plasma. In summary, our study showed that in vitro addition of idarucizumab to plasma samples from patients increases thrombin generation. The use of idarucizumab to neutralize dabigatran in patient plasma samples as well as the clinical relevance of in vitro increased thrombin generation induced by idarucizumab needs further investigation.Mojca Božič MijovskiRickard E. MalmströmNina VeneJovan P. AntovicAlenka MavriNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Mojca Božič Mijovski Rickard E. Malmström Nina Vene Jovan P. Antovic Alenka Mavri The in vitro addition of idarucizumab to plasma samples from patients increases thrombin generation
description	Abstract Dabigatran interferes with many coagulation tests. To overcome this obstacle the use of idarucizumab as an in vitro antidote to dabigatran has been proposed. The aim of this study was to test the effect of idarucizumab as an in vitro antidote to dabigatran in ex vivo plasma samples from routine clinical patients examined by a thrombin generation assay (TGA). From 44 patients with atrial fibrillation five blood samples were collected. Thrombin generation was measured in all samples before and after the addition of idarucizumab. When idarucizumab was added to baseline plasma (no dabigatran), it caused a significantly shorter Lag Time and Time to Peak Thrombin, and a higher Peak Thrombin and Endogenous Thrombin Potential (ETP) of TGA. Similar results were obtained when idarucizumab was added to dabigatran-containing plasma, with TGA parameters comparable to baseline + idarucizumab plasma, but not to baseline plasma. In summary, our study showed that in vitro addition of idarucizumab to plasma samples from patients increases thrombin generation. The use of idarucizumab to neutralize dabigatran in patient plasma samples as well as the clinical relevance of in vitro increased thrombin generation induced by idarucizumab needs further investigation.
format	article
author	Mojca Božič Mijovski Rickard E. Malmström Nina Vene Jovan P. Antovic Alenka Mavri
author_facet	Mojca Božič Mijovski Rickard E. Malmström Nina Vene Jovan P. Antovic Alenka Mavri
author_sort	Mojca Božič Mijovski
title	The in vitro addition of idarucizumab to plasma samples from patients increases thrombin generation
title_short	The in vitro addition of idarucizumab to plasma samples from patients increases thrombin generation
title_full	The in vitro addition of idarucizumab to plasma samples from patients increases thrombin generation
title_fullStr	The in vitro addition of idarucizumab to plasma samples from patients increases thrombin generation
title_full_unstemmed	The in vitro addition of idarucizumab to plasma samples from patients increases thrombin generation
title_sort	in vitro addition of idarucizumab to plasma samples from patients increases thrombin generation
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/a25cf96b94804dc3a82f82c18ba9f6e4
work_keys_str_mv	AT mojcabozicmijovski theinvitroadditionofidarucizumabtoplasmasamplesfrompatientsincreasesthrombingeneration AT rickardemalmstrom theinvitroadditionofidarucizumabtoplasmasamplesfrompatientsincreasesthrombingeneration AT ninavene theinvitroadditionofidarucizumabtoplasmasamplesfrompatientsincreasesthrombingeneration AT jovanpantovic theinvitroadditionofidarucizumabtoplasmasamplesfrompatientsincreasesthrombingeneration AT alenkamavri theinvitroadditionofidarucizumabtoplasmasamplesfrompatientsincreasesthrombingeneration AT mojcabozicmijovski invitroadditionofidarucizumabtoplasmasamplesfrompatientsincreasesthrombingeneration AT rickardemalmstrom invitroadditionofidarucizumabtoplasmasamplesfrompatientsincreasesthrombingeneration AT ninavene invitroadditionofidarucizumabtoplasmasamplesfrompatientsincreasesthrombingeneration AT jovanpantovic invitroadditionofidarucizumabtoplasmasamplesfrompatientsincreasesthrombingeneration AT alenkamavri invitroadditionofidarucizumabtoplasmasamplesfrompatientsincreasesthrombingeneration
_version_	1718393348540071936

The in vitro addition of idarucizumab to plasma samples from patients increases thrombin generation

Ejemplares similares